Keytruda (Pembrolizumab)
- Medicine Name: Keytruda
- API: Pembrolizumab
- Dosage Form & Strength: Injection: 100 mg/4 mL (25 mg/mL) solution in a single-dose vial
- Manufactured By: Merck
Keytruda (pembrolizumab) is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of various types of cancer, including:
Melanoma:
- for the treatment of patients with unresectable or metastatic melanoma.
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma after complete resection.
Non-Small Cell Lung Cancer (NSCLC):
- in conjunction with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- in conjunction with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- as a monotherapy for the first-line treatment of patients with NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
- as a monotherapy for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy.
- for the treatment of patients with resectable (tumors ≥4 cm or node-positive) NSCLC along with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- as a monotherapy, for adjuvant treatment after resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
Head and Neck Squamous Cell Cancer (HNSCC):
- in conjunction with platinum and FU for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC.
- as a monotherapy for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC whose tumors express PD-L1.
- as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Classical Hodgkin Lymphoma (cHL):
- for the treatment of adult patients with relapsed or refractory cHL.
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy.
Primary Mediastinal Large B-Cell Lymphoma (PMBCL):
- for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.
- in conjunction with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- as a monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or after platinum-containing chemotherapy or within 1 year of neoadjuvant or adjuvant therapy with platinum-containing chemotherapy.
- as a monotherapy for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Microsatellite Instability-High or Mismatch Repair Deficient Cancer:
- for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, that have progressed following prior therapy and who have no satisfactory alternative options.
Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC):
- for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).
Gastric Cancer:
- in conjunction with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
- in conjunction with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Esophageal Cancer:
- for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with an epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either along with platinum- and fluoropyrimidine-based chemotherapy or as monotherapy after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10).
Cervical Cancer:
- in conjunction with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.
- in conjunction with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1).
- as a monotherapy for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1).
Hepatocellular Carcinoma (HCC):
- for the treatment of patients with HCC secondary to hepatitis B who have previously been treated with systemic therapy other than a PD1/PD-L1-containing regimen.
Biliary Tract Cancer (BTC):
- in conjunction with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
Merkel Cell Carcinoma:
- for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Renal Cell Carcinoma (RCC):
- in conjunction with axitinib, for the first-line treatment of adult patients with advanced RCC.
- in conjunction with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
- for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or after nephrectomy and resection of metastatic lesions.
Endometrial Carcinoma:
- in conjunction with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR), who have disease progression following prior systemic therapy in any setting, and who are not candidates for curative surgery or radiation.
- as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Tumor Mutational Burden-High (TMB-H) Cancer:
- for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors, that have progressed after prior therapy and who have no satisfactory alternative options.
Cutaneous Squamous Cell Carcinoma (cSCC):
- for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that can not be cured by surgery or radiation.
Triple-Negative Breast Cancer (TNBC):
- for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment following surgery.
- in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1.
Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma:
- for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-cell lymphoma in adults.
Recommended Dosage: The recommended dosage of Keytruda (pembrolizumab) varies based on the type of cancer being treated and should be determined by the healthcare provider. For most indications, the typical dosage is 200 mg administered as an intravenous infusion over 30 minutes every three weeks, or 400 mg every six weeks. Treatment continues until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. Dosage adjustments are based on individual patient response and tolerability. It’s crucial to follow the specific dosage and schedule prescribed by the healthcare provider, as it may vary depending on the type and stage of cancer being treated.
- Treatment with Keytruda 100 mg/4 mL can cause immune-mediated reactions affecting different organs. Common ones include pneumonitis, colitis, hepatitis, endocrinopathies (like thyroiditis, adrenal insufficiency, and type 1 diabetes), and nephritis. Patients should be monitored for signs and symptoms of these conditions and managed appropriately with corticosteroids or treatment discontinuation if severe reactions occur.
- Infusion reactions, including fever, chills, shortness of breath, flushing, and hypotension, can occur. Most reactions are mild to moderate, but severe cases require stopping the infusion and providing medical treatment. Patients should be closely monitored during and after administration.
- Hepatotoxicity is a potential side effect, with elevated liver enzymes and bilirubin levels. Liver function should be regularly monitored, and patients should report symptoms such as jaundice or right upper quadrant pain. Severe cases may require treatment interruption or discontinuation.
- Keytruda can cause endocrine disorders such as hypothyroidism, hyperthyroidism, adrenal insufficiency, and diabetes. Regular monitoring of thyroid function and blood glucose levels is recommended. Symptoms like fatigue, weight changes, or increased thirst and urination should be reported promptly.
- Keytruda can cause nephritis, leading to renal dysfunction. Monitoring of renal function through serum creatinine and urinalysis is necessary. Patients should be vigilant for symptoms such as decreased urine output or swelling and report them immediately.
- Severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), can occur. Patients should be instructed to report any rash, blistering, or peeling of the skin. Discontinuation of Keytruda may be required in severe cases.
- Keytruda can cause fetal harm when administered to pregnant women. Women of childbearing potential should use effective contraception during treatment and for four months after the last dose. It is not known if pembrolizumab is excreted in human milk, so breastfeeding should be avoided during treatment and for four months after the last dose.
What documents are required to import KEYTRUDA to India?
KEYTRUDA (pembrolizumab) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order be confirmed?
- The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
Is KEYTRUDA available in India?
KEYTRUDA (pembrolizumab injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Keytruda in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
KEYTRUDA can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of KEYTRUDA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Keytruda 100 mg/4 mL price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source the KEYTRUDA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Keytruda®?
Pembrolizumab is a Generic Name for the trade name drug Keytruda®.
What is the Manufacturer’s Name of Keytruda®?
Keytruda® is manufactured by Merck.
Is Keytruda® approved by the FDA?
Yes, Keytruda® is approved by the FDA. Date of first approval: September 4, 2014.
What is the dosage and form of Keytruda® supplied?
Keytruda® is supplied as injections: 100 mg/4 mL (25 mg/mL) solution in a single-dose vial for intravenous administration.
How much does Keytruda® cost in India?
Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Keytruda in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Keytruda®?
Keytruda® should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F), protected from light. Do not freeze or shake. Store in the original carton to protect it from the light.
Is it safe to buy Keytruda® online in India?
Yes, one can buy Keytruda online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Keytruda® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.